https://doi.org/10.1016/s1470-2045(18)30570-9
I
Ingrid A.M. Mandjes
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
115
Papers
2.7K
Citations
22
h-index
32
i10-index
Ingrid A.M. Mandjes is an academic researcher from Dutch Cancer Society. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Cells and Metastasis & Immunotherapy and Immune Responses. The author has an h-index of 22, co-authored 98 publications.
Papers by this author
worksNeoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
2018 · The Lancet Oncology · 421 citations
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
2013 · Breast Cancer Research and Treatment · 114 citations
https://doi.org/10.1007/s10549-013-2620-0
Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
2011 · Breast Cancer Research and Treatment · 86 citations
https://doi.org/10.1007/s10549-011-1488-0
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy
2009 · Annals of Oncology · 55 citations
https://doi.org/10.1093/annonc/mdp348
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
2024 · Nature Medicine · 53 citations
https://doi.org/10.1038/s41591-024-03249-3
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
2023 · Nature Cancer · 36 citations
https://doi.org/10.1038/s43018-023-00542-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat